01Jun 2023
Depot medroxyprogesterone acetate and endometrial cancer: A multicenter case–control study

Depot medroxyprogesterone acetate and endometrial cancer: A multicenter case–control study

This multicenter case-control study evaluated the relationship between depot medroxyprogesterone acetate (DMPA) use and endometrial cancer. The study included 378 patients with endometrial cancer and 1134 control subjects. The results indicated that ever using DMPA was associated with a 70% reduced risk of endometrial cancer. Additionally, for every 3 months of DMPA use, the risk of endometrial cancer decreased by 3%. The protective effect of DMPA was consistent across different subtypes of endometrial cancer. The study suggests that DMPA use is inversely associated with endometrial cancer risk, regardless ofthe cancer subtype.

  • #gynaecology - ivf

Like

Save

Share